Grade ≥3 toxicity and treatment compliance (n = 101 patients)
| . | Induction 4 wk . | Consolidation 8 wk . | Early continuation 6 wk . | Reinduction 6 wk . | Continuation A 40 wk . | Continuation B 52 wk . |
|---|---|---|---|---|---|---|
| CNS toxicity, n of patients | 0 | 1 | 0 | 0 | 0 | 0 |
| Respiratory toxicity, n of patients | 0 | 0 | 0 | 0 | 0 | 0 |
| Hepatic toxicity, n of patients | 10 | 13 | 1 | 10 | 7 | 10 |
| Renal toxicity, n of patients | 3 | 4 | 0 | 4 | 0 | 1 |
| Hypersensitivity to L-asparaginase, n of patients | 1* | NA | NA | 53/100 | NA | NA |
| Neutropenia and fever, n of episodes (n of patients) | 61 (34) | 19 (10) | 20 (11) | 32 (19) | 115 (44) | 116 (54) |
| Blood cultures, n positive | 9 (5 gram+, 4 gram−) | 5 (2 gram+, 3 gram−) | None | 3 (3 gram+) | 5 (4 gram+, 1 gram−) | 8 (8 gram+) |
| Hospitalization, median d (range) | 3 (4-5) | 5 (2-15) | 4 (2-7) | 4 (2-19) | 2.5 (1-18) | 5 (1-22) |
| Deaths from toxicity, n | 0 | 0 | 0 | 0 | 0 | 1† |
| Received planned therapy, n of patients‡ | 85 | 94 | 101 | 47 | 101 | 100 |
| . | Induction 4 wk . | Consolidation 8 wk . | Early continuation 6 wk . | Reinduction 6 wk . | Continuation A 40 wk . | Continuation B 52 wk . |
|---|---|---|---|---|---|---|
| CNS toxicity, n of patients | 0 | 1 | 0 | 0 | 0 | 0 |
| Respiratory toxicity, n of patients | 0 | 0 | 0 | 0 | 0 | 0 |
| Hepatic toxicity, n of patients | 10 | 13 | 1 | 10 | 7 | 10 |
| Renal toxicity, n of patients | 3 | 4 | 0 | 4 | 0 | 1 |
| Hypersensitivity to L-asparaginase, n of patients | 1* | NA | NA | 53/100 | NA | NA |
| Neutropenia and fever, n of episodes (n of patients) | 61 (34) | 19 (10) | 20 (11) | 32 (19) | 115 (44) | 116 (54) |
| Blood cultures, n positive | 9 (5 gram+, 4 gram−) | 5 (2 gram+, 3 gram−) | None | 3 (3 gram+) | 5 (4 gram+, 1 gram−) | 8 (8 gram+) |
| Hospitalization, median d (range) | 3 (4-5) | 5 (2-15) | 4 (2-7) | 4 (2-19) | 2.5 (1-18) | 5 (1-22) |
| Deaths from toxicity, n | 0 | 0 | 0 | 0 | 0 | 1† |
| Received planned therapy, n of patients‡ | 85 | 94 | 101 | 47 | 101 | 100 |